Implementation and Evaluation of an Expanded Bilingual Electronic Symptom Management Program across a Multi-site, Fully-integrated Comprehensive Cancer Center
在多站点、完全集成的综合癌症中心实施和评估扩展的双语电子症状管理计划
基本信息
- 批准号:9625977
- 负责人:
- 金额:$ 766.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-24 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAdultAffectAftercareAmbulatory CareAmbulatory Care FacilitiesAnxietyAreaAttentionBiometryCaringClinicClinicalClinical TrialsColorComprehensive Cancer CenterConsensusCustomDataData CollectionDevelopmentEffectivenessElectronic Health RecordElementsEngineeringEnrollmentEthnic OriginEvaluationFatigueGuidelinesGynecologic OncologyHealth systemHealthcareHealthcare SystemsHematologyHospitalsHybridsImpairmentInformaticsInformation SystemsInpatientsInterventionJointsKnowledgeMalignant NeoplasmsMeasurementMedicineMental DepressionModelingMonitorNatureOnline SystemsOutcomeOutcome AssessmentOutpatientsPainParticipantPatient Outcomes AssessmentsPatient-Focused OutcomesPatientsPharmacologyPhasePhysical FunctionPreventionPsychometricsQuality of lifeRandomizedRandomized Clinical TrialsRandomized Controlled Clinical TrialsReportingResearchResearch DesignScienceSelf EfficacySelf ManagementSeveritiesSiteSocial FunctioningSocioeconomic StatusSourceStatistical Data InterpretationSupportive careSymptomsSystemTestingTimeTreatment-Related CancerUniversitiesWorkbasebilingualismcancer therapycare deliveryclinical practicecomputerizedemotional distresshealth care deliveryhealth care service utilizationimplementation trialindividual patientinnovationmental functiononcologypain symptompatient engagementpatient orientedpatient populationprogramsracial disparitysexsurvivorshipsymptom managementsymptomatic improvementtooltreatment as usualtrial design
项目摘要
Cancer, and cancer treatment, cause many symptoms that can adversely affect quality of life. Despite the
development of improved symptom management interventions, and several evidence- and consensus-based
guidelines, their timely delivery remains uneven in the health care system. Our research center, Northwestern
University IMPACT (NU IMPACT), builds upon an integrated cancer symptom monitoring and management
system (NMPRO), currently deployed by our health care delivery system. We will test the effectiveness of a
system-wide symptom management intervention when implemented across the Northwestern Memorial
HealthCare Corporation (NMHC) outpatient oncology clinics. Using a clinic-level randomized roll-out
implementation trial design, we will further test, using an embedded patient-level randomized controlled clinical
trial, the effectiveness of an enhanced care (EC) approach aimed to engage participants actively, and to
increase self-efficacy, in the monitoring and managing of their symptoms. The existing NMPRO will constitute
usual care (UC), and added patient engagement and activation features will comprise the EC condition. This
innovative hybrid trial design allows for a within- and between-site evaluation of implementation along with a
sufficiently powered group-based comparison to demonstrate effectiveness on individual patient outcomes.
We propose three specific aims that target both patient- and system-level outcomes. Aim 1: Implement a
fully-integrated oncology symptom assessment and management program across six clinical units that are part
of the NMHC healthcare delivery system; Aim 2: Evaluate the impact of the program by conducting a hybrid
Type I effectiveness-implementation trial to evaluate the enhanced care program (EC: symptom monitoring &
self-management intervention), relative to usual care (UC) on patient- and system-level outcomes; Aim 3:
Identify facilitators and barriers to implementation and disseminate to other health systems. We will enroll an
estimated 12,671 participants. To address possible contamination effects within each clinical unit, and allow for
unit-level data collection for pre- and post-implementation comparison within and across clinical units, 50% will
be enrolled and followed prior to program implementation. The other half will be enrolled post-implementation
and will be randomly assigned at a 1:1 ratio (stratified by sex and cancer phase; curative intent, non-curative
intent & survivorship) to UC versus EC. Fatigue, pain, anxiety, and depression will be assessed using
PROMIS® computerized adaptive tests (CATs). In addition, we will assess patient clinical outcomes, including
healthcare utilization, and cancer treatment delivery outcomes. The NU IMPACT study design allows joint
evaluation of system-level implementation and patient-level effectiveness metrics. An extensive array of
longitudinal EHR data will be integrated using custom informatics tools and deployed for statistical analysis
using plans that blend psychometric and biostatistical outcome evaluation models. Successful elements of this
intervention approach will then be extended to widespread adoption.
癌症和癌症治疗会引起许多症状,这些症状会对生活质量产生不利影响。尽管
制定改进的症状管理干预措施,以及一些基于证据和共识的
尽管这些服务的及时提供与指导方针相一致,但在卫生保健系统中仍然不均衡。我们的研究中心,西北大学
大学IMPACT(NU IMPACT)建立在综合癌症症状监测和管理的基础上
系统(NMPRO),目前由我们的医疗保健提供系统部署。我们将测试一种
在西北纪念医院实施全系统症状管理干预
医疗保健公司(NMHC)门诊肿瘤诊所。使用临床水平的随机展开
实施试验设计后,我们将进一步检验,采用嵌入式患者水平随机对照临床
试验,加强护理(EC)方法的有效性,旨在积极吸引参与者,并
提高自我效能,监测和管理他们的症状。现有的NMPRO将构成
常规护理(UC)以及增加的患者参与和激活功能将构成EC条件。这
创新的混合试验设计允许在研究中心内和研究中心间对实施沿着进行评价,
充分把握度的基于组的比较,以证明对个体患者结局的有效性。
我们提出了三个具体的目标,针对患者和系统级的结果。目标1:实施
一个完全集成的肿瘤症状评估和管理计划,横跨六个临床单位,
目标2:通过进行混合评估该计划的影响
I类有效性-实施试验,以评估加强护理计划(EC:症状监测和
自我管理干预),相对于常规护理(UC)对患者和系统水平结局的影响;目标3:
确定执行的促进因素和障碍,并向其他卫生系统传播。我们将招收一名
估计有12,671人参加。为了解决每个临床单元内可能的污染影响,并考虑到
在临床单位内部和之间进行实施前和实施后比较的单位级数据收集,50%将
在项目实施前进行登记和跟踪。另一半将在实施后入组
并将以1:1的比例随机分配(按性别和癌症分期分层;治愈性,非治愈性
意图和生存率)到UC与EC。疲劳、疼痛、焦虑和抑郁将使用
PROMIS®计算机化适应性测试(CAT)。此外,我们还将评估患者的临床结局,包括
医疗保健利用和癌症治疗交付结果。NU IMPACT研究设计允许联合
评估系统级实施和患者级有效性指标。一系列广泛的
纵向EHR数据将使用定制信息学工具进行整合,并用于统计分析
使用混合心理测量和生物统计结果评估模型的计划。成功要素
然后将干预方法推广到广泛采用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID CELLA其他文献
DAVID CELLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID CELLA', 18)}}的其他基金
Implementation and Evaluation of an Expanded Bilingual Electronic Symptom Management Program across a Multi-site, Fully-integrated Comprehensive Cancer Center
在多站点、完全集成的综合癌症中心实施和评估扩展的双语电子症状管理计划
- 批准号:
10378999 - 财政年份:2021
- 资助金额:
$ 766.57万 - 项目类别:
Northwestern University Clinical Outcome Assessment Team (NUCOAT)
西北大学临床结果评估小组 (NUCOAT)
- 批准号:
10016244 - 财政年份:2019
- 资助金额:
$ 766.57万 - 项目类别:
Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients with Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to THerapY: TheEMPATHY Pilot Study
评估慢性粒细胞白血病患者日常护理中患者报告的结果监测,以提高治疗的依从性和临床反应:EMPATHY 试点研究
- 批准号:
9982264 - 财政年份:2019
- 资助金额:
$ 766.57万 - 项目类别:
Northwestern University Clinical Outcome Assessment Team (NUCOAT)
西北大学临床结果评估小组 (NUCOAT)
- 批准号:
10678643 - 财政年份:2019
- 资助金额:
$ 766.57万 - 项目类别:
Northwestern University Clinical Outcome Assessment Team (NUCOAT)
西北大学临床结果评估小组 (NUCOAT)
- 批准号:
10475575 - 财政年份:2019
- 资助金额:
$ 766.57万 - 项目类别:
ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health
ECHO PRO 研究资源:用于评估环境暴露和儿童健康的基于发展的测量科学框架
- 批准号:
9263349 - 财政年份:2016
- 资助金额:
$ 766.57万 - 项目类别:
Amplification of Racial and Social Inequalities in Response to the COVID-19 Pandemic: Impacts on Child Academic and Psychological Outcomes
应对 COVID-19 大流行的种族和社会不平等的加剧:对儿童学业和心理结果的影响
- 批准号:
10205654 - 财政年份:2016
- 资助金额:
$ 766.57万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 766.57万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 766.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 766.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 766.57万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 766.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 766.57万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 766.57万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 766.57万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 766.57万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 766.57万 - 项目类别:
Standard Grant